Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update

About this update from Alligator Bioscience Ab

LUND, SE / ACCESS Newswire / February 12, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced its interim results for the third quarter of 2025 and provided a business update. "The fourth quarter of 2025 was marked by continued execution on our strategy, focusing on advancing mitazalimab towards initiation of registrational trials, strengthening the scientific foundation of our pipeline, and increasing financial flexibility. While the external funding environment for biotech remains challenging, we have concentrated on areas within our control - generating high-quality data, maintaining operational discipline, and making focused investments that position the company to progress mitazalimab toward late-stage development." Søren Bregenholt, CEO of Alligator Bioscience BUSINESS UPDATE Mitazalimab ATOR-4066 HLX22 Company / Financial position FINANCIAL SUMMARY FOR Q4 AND YEAR-END 2025 The financial summaries for the quarterly periods ending 31 December 2025 and 31 December 2024 are presented below. The financial summaries for the year-to-date periods ending 31 December 2025 and 31 December 2024 are presented below. The full report is attached as a PDF, and is also available on the company's website: https://alligatorbioscience.se/en/investors/financial-reports/ Alligator will host a webinar on Thursday, 12 February 2026, at 3 p.m. CEST/ 9 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report, which will be followed by a Q&A session. The call will be held in English. Attendees need to register by following >>this link<< . For further information, please contact: Søren Bregenholt, CEO E-mail: [email protected] Phone: +46 (0) 46 540 82 00 Johan Giléus, CFO E-mail: [email protected] Phone: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on 12 February 2026. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . Attachments 2025 Q4 EN VF SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire

View stock analysis, news, and events for Alligator Bioscience Ab